Vasorelaxant effect of 3,5,4′-trihydroxy-trans-stilbene (resveratrol) and its underlying mechanism
Resveratrol is found in numerous plant-based foods and beverages and is known to have an impact on the cardiovascular system. The aim of this study was to investigate the vasorelaxant effect of resveratrol and its underlying mechanisms by employing an aortic ring assay model. Resveratrol caused relaxation of aortic rings that had been precontracted with phenylephrine in the presence of endothelium or with potassium chloride in endothelium-intact aortic rings. The vasorelaxant effect was decreased in the absence of an endothelium. The mechanisms underlying the vasorelaxant effect of resveratrol were determined through the addition of antagonists. In the presence of the endothelium, indomethacin (a nonselective cyclooxygenase inhibitor), methylene blue (cyclic guanosine monophosphate lowering agent), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, selective soluble guanylate cyclase inhibitor), Nω-nitro-l-arginine methyl ester (L-NAME, nitric oxide synthase inhibitor), tetraethylammonium (TEA, nonselective calcium activator potassium channel blocker), 4-aminopyridine (4-AP, voltage-dependent K+ channel blocker), barium chloride (BaCl2, inwardly rectifying K+ channel blocker), glibenclamide (non-specific ATP-sensitive K+ channel blocker) and propranolol (β-adrenergic receptor blocker) led to a significant reduction in the vasorelaxation effect induced by resveratrol. Resveratrol was also found to reduce Ca2+ release from the sarcoplasmic reticulum and block calcium channels. In conclusion, resveratrol targets multiple signalling pathways for exerting its vasorelaxant effects in the rat aortic ring model in both the presence and absence of endothelium.
KeywordsResveratrol Stilbenoids Vasorelaxant activity Aortic ring assay Potassium and Calcium channels
The author would like to express deepest appreciation to all the authors who made contributions to this research. This project was supported by Fundamental Research Grant Scheme (FRGS) (203/PFARMASI/6711306), Exploratory Research Grant Scheme (ERGS) (203/PFARMASI/6730122) and Universiti Sains Malaysia-Research University Grants (1001/PFARMASI/812195).
Author contribution statement
The manuscript was written by CST. The experiment and vasorelaxant study were conducted by CST, YCL and WYT. The overall process was supervised by Dr. MFY.
Compliance with ethical standards
Conflict of interest
We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. The authors declare no conflict of interest.
- Aubin MC, Lajoie C, Clement R, Gosselin H, Calderone A, Perrault LP (2008) Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 325:961–968CrossRefGoogle Scholar
- Bastinetto S, Menard C, Quirion R (2015) Neuroprotective action of resveratrol. Biochem Biophys Acta 1852:1195–1201Google Scholar
- Subramanian M, Balasubramanian P, Garver H, Northcott C, Zhao H, Haywood JR, Fink GD, MohanKumar SM, MohanKumar PS (2011) Chronic estradiol-17 beta exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am J Physiol Regul Integr Comp Physiol 300:1560–1568CrossRefGoogle Scholar
- Toklu HZ, Sehirli O, Ersahin M, Suleymanoglu S, Yiginer O, Emekli-Alturfan E, Yarat A, Yegen BC, Sener G (2010) Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol 62(12):1784–1793CrossRefGoogle Scholar